Allovir Stock Current Liabilities
| ALVR Stock | USD 0.77 0.03 3.75% |
Allovir fundamentals help investors to digest information that contributes to Allovir's financial success or failures. It also enables traders to predict the movement of Allovir Stock. The fundamental analysis module provides a way to measure Allovir's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Allovir stock.
As of 10/20/2024, Total Current Liabilities is likely to drop to about 21.2 M. In addition to that, Non Current Liabilities Total is likely to drop to about 15.8 M. Allovir | Current Liabilities |
Allovir Company Current Liabilities Analysis
Allovir's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Allovir Current Liabilities | 53.23 M |
Most of Allovir's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Allovir is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Allovir Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Allovir is extremely important. It helps to project a fair market value of Allovir Stock properly, considering its historical fundamentals such as Current Liabilities. Since Allovir's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Allovir's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Allovir's interrelated accounts and indicators.
Click cells to compare fundamentals
Allovir Current Liabilities Historical Pattern
Today, most investors in Allovir Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Allovir's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Allovir current liabilities as a starting point in their analysis.
Allovir Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Allovir Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Allovir has a Current Liabilities of 53.23 M. This is 96.96% lower than that of the Biotechnology sector and 90.2% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.33% higher than that of the company.
Allovir Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Allovir's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Allovir could also be used in its relative valuation, which is a method of valuing Allovir by comparing valuation metrics of similar companies.Allovir is currently under evaluation in current liabilities category among its peers.
Allovir Current Valuation Drivers
We derive many important indicators used in calculating different scores of Allovir from analyzing Allovir's financial statements. These drivers represent accounts that assess Allovir's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Allovir's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7B | 1.0B | 812.4M | 393.2M | 70.7M | 67.2M | |
| Enterprise Value | 1.6B | 920.0M | 640.8M | 322.5M | 8.0M | 7.6M |
Allovir Fundamentals
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | (32.38 M) | ||||
| Shares Outstanding | 115.36 M | ||||
| Shares Owned By Insiders | 49.21 % | ||||
| Shares Owned By Institutions | 42.99 % | ||||
| Number Of Shares Shorted | 5.5 M | ||||
| Price To Book | 0.74 X | ||||
| Gross Profit | 165 K | ||||
| EBITDA | (180.93 M) | ||||
| Net Income | (190.42 M) | ||||
| Cash And Equivalents | 172.67 M | ||||
| Cash Per Share | 1.91 X | ||||
| Total Debt | 27.43 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 8.18 X | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (124.45 M) | ||||
| Short Ratio | 34.80 X | ||||
| Earnings Per Share | (1.23) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 0.98 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 89.19 M | ||||
| Total Asset | 190.8 M | ||||
| Retained Earnings | (656.19 M) | ||||
| Working Capital | 159.27 M | ||||
| Current Asset | 61.62 M | ||||
| Current Liabilities | 53.23 M | ||||
| Net Asset | 190.8 M |
About Allovir Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Allovir's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allovir using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allovir based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Allovir
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.Moving together with Allovir Stock
| 0.7 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
| 0.63 | BMY | Bristol Myers Squibb | PairCorr |
Moving against Allovir Stock
| 0.66 | ERNA | Eterna Therapeutics | PairCorr |
| 0.62 | PTN | Palatin Technologies | PairCorr |
| 0.59 | DYAI | Dyadic International | PairCorr |
| 0.57 | VALN | Valneva SE ADR | PairCorr |
| 0.57 | MBIO | Mustang Bio | PairCorr |
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.